Tegonat TabletsProduct Description:Tegonat is a fixed-dose combination of Tegafur, Gimeracil, and Oteracil, developed to treat advanced gastric cancer and metastatic colorectal cancer. This oral chemotherapy regimen is bioequivalent to Teysuno® (S-1) and works by enhancing the anti-cancer activity of 5-fluorouracil (5-FU) while reducing its gastrointestinal side effects.Tegonat is formulated to maximize anti-tumor efficacy and minimize toxicity by combining: Tegafur: A prodrug of 5-FU (cytotoxic agent) Gimeracil: A dihydropyrimidine dehydrogenase (DPD) inhibitor that increases 5-FU bioavailability Oteracil: Reduces gastrointestinal side effects by blocking 5-FU phosphorylation in the gut Indications: Advanced gastric (stomach) cancer, in combination with cisplatin Metastatic colorectal cancer in patients unable to tolerate standard fluoropyrimidine therapies May be considered for other solid tumors as determined by oncology specialists Mechanism of Action:Tegonat acts through modulation of 5-FU metabolism. Tegafur converts to 5-FU in the body, Gimeracil inhibits the breakdown of 5-FU to prolong its action, and Oteracil selectively reduces GI toxicity, offering a balanced and tolerable chemotherapy regimen.Key Features: Oral fluoropyrimidine therapy with improved tolerability Equivalent to Teysuno® / TS-One used widely in Japan and Europe Convenient oral administration, reducing the need for IV infusions
